Results 21 to 30 of about 259,269 (302)

Use of Tocilizumab in Management of Post-Operative Myelomonocytic Leukemoid Reaction

open access: yesLeukemia Research Reports, 2020
Interleukin 6 receptor (IL6R) inhibitor, tocilizumab, has been effectively used in the treatment of cytokine release syndrome in patients receiving chimeric antigen receptor T-cell therapy.
Megan Melody   +6 more
doaj   +1 more source

Psoriatic arthritis successfully treated with second-line anti-interleukin-6 treatment: a case report and review of the literature 

open access: yesJournal of Medical Case Reports, 2022
Background Psoriatic arthritis treatment with antitumor necrosis factor has been shown to reduce disease activity. Nonetheless, more than 30% of patients do not achieve a sufficient response to tumor necrosis factor blockers.
Tatsuhiko Kutsuna   +6 more
doaj   +1 more source

Effect of IRAK1/4 inhibitor on IL-1β, IL-6, INF-γ and TNF-α expression in breast cancer cells of several lines [PDF]

open access: yesThe Ukrainian Biochemical Journal, 2021
Recent studies have shown that inflammation mediated via interleukin-1 receptor-associated kinases (IRAKs) is associated with cancer cells drug resistance.
M. Rezaei   +4 more
doaj   +1 more source

Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist : a Mendelian randomisation analysis [PDF]

open access: yes, 2015
Funded by: UK Medical Research Council, British Heart Foundation, UK National Institute for Health Research, National Institute for Health Research Cambridge Biomedical Research Centre, European Research Council, and European Commission Framework ...
D. F. Easton (7608179)   +874 more
core   +1 more source

Practical issues in the use of levilimab, a novel interleukin-6 receptor inhibitor, in patients with rheumatoid arthritis

open access: yesClinical pharmacology and therapy, 2022
Levilimab is a monoclonal antibody targeting interleukin-6 receptors and having a potent anti-inflammatory activity. Efficacy and safety of levilimab for treatment of rheumatoid arthritis were established in multicenter, double blind, placebo-controlled clinical trials AURORA and SOLAR.
S. Moiseev   +6 more
openaire   +1 more source

Contribution of Extracellular Signal-Regulated Kinase to UTP-Induced Interleukin-6 Biosynthesis in HaCaT Keratinocytes

open access: yesJournal of Pharmacological Sciences, 2006
UTP causes interleukin (IL)-6 production via mRNA expression through P2Y2/P2Y4 receptors in human HaCaT keratinocytes. In the present study, we analyzed the mechanism of UTP-induced IL-6 production in these cells.
Daisaku Kobayashi   +2 more
doaj   +1 more source

A GLP-1 Analog Liraglutide Reduces Intimal Hyperplasia After Coronary Stent Implantation via Regulation of Glycemic Variability and NLRP3 Inflammasome/IL-10 Signaling in Diabetic Swine

open access: yesFrontiers in Pharmacology, 2020
ObjectiveThis study aimed to explore whether treatment with the glucagon-like peptide-1 (GLP-1) analog liraglutide reduces intimal hyperplasia after coronary stent implantation via regulation of glycemic variability, the NLRP3 inflammasome, and IL-10 in ...
Jinggang Xia   +9 more
doaj   +1 more source

Cytokine-induced Src homology 2 protein (CIS) promotes T cell receptor-mediated proliferation and prolongs survival of activated T cells [PDF]

open access: yes, 2000
Copyright @ 2000 The Rockefeller University Press. This article is shared under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/ and http://creativecommons ...
Sjögren, HO   +25 more
core   +1 more source

Leptin induces IL-6 expression through OBRl receptor signaling pathway in human synovial fibroblasts. [PDF]

open access: yesPLoS ONE, 2013
BACKGROUND: Leptin, an adipocyte-secreted hormone that centrally regulates weight control, may exert proinflammatory effects in the joint, depending on the immune response.
Wei-Hung Yang   +6 more
doaj   +1 more source

Two Biosensors for the Determination of Interleukin-6 in Blood Plasma by Array SPRi

open access: yesBiosensors, 2022
Interleukin-6 (IL-6) is a biomarker of inflammation, the advanced stage of COVID-19, and several cancers, including ovarian cancer. Two biosensors for the determination of IL-6 in blood plasma by array SPRi have been developed.
Beata Szymanska   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy